Background ST-segment elevation myocardial infarction (STEMI) patients are treated with
dual antiplatelet therapy comprising aspirin and a P2Y 12 inhibitor. Clopidogrel is widely …

Rationale In patients with ST-segment elevation myocardial infarction (STEMI) who undergo
primary percutaneous coronary intervention (pPCI), the use of dual antiplatelet therapy is …

Objectives The aim of this study was to evaluate prospectively the clinical impact of routine
transmission of CYP2C19 genotype in the management of acute ST-segment elevation …

Background To mitigate the risk of stent thrombosis, patients treated by percutaneous
coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin …

Background Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome
(ACS) patients. However, these P2Y12 inhibitors increase bleeding risk compared to …

In patients undergoing percutaneous coronary intervention (PCI), the standard of care is
dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and …

Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …

Background: Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with
myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary …

Background: CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after
percutaneous coronary intervention, but the clinical impact of implementing CYP2C19 …

Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous
coronary intervention (PCI) improves clinical outcomes. Although results for the increased …